Actualizado 14/06/2007 16:10
- Comunicado -

Boehringer Ingelheim Initiates SPRING Study of Aptivus(R) (tipranavir) in Diverse Group of Highly Treatment-Experienced

This release is from the Corporate Headquarters of Boehringer Ingelheim and is intended for all international markets. This being the case, please be aware that there may be some differences between countries regarding specific medical information including licensed uses. Please take account of this when referring to the material.

References:

(i) Lab Tests Online. American Association for Clinical Chemistry. Therapeutic Drug Monitoring. Available at: http://www.labtestsonline.org/understand.... Accessed on March 27, 2007.

(ii) UNAIDS/WHO: 2006 Report on the global AIDS epidemic

    
    Web site: http://www.boehringer-ingelheim.com/hiv
              http://www.clinicaltrials.gov

Judith von Gordon for Boehringer Ingelheim GmbH, +49-61-32-77-3582, or fax, +49-61-32-77-6601

Contenido patrocinado